MindMed’s Phase Study for Generalized Anxiety Disorder Enrolls +50% of Participants

LOS ANGELES– Mind Medicine (MindMed), a clinical-stage biopharmaceutical company focused on developing treatments for brain health disorders, provided an update on its Phase 2b study evaluating MM-120 (lysergide D-tartrate) for generalized anxiety disorder (GAD). The study has enrolled and dosed over 50% of the targeted participants and is on track for topline results to be announced in late 2023.

The Phase 2b trial is a randomized, double-blind, placebo-controlled study designed to optimize the dosage of MM-120 for GAD patients. Up to 200 participants will be enrolled and randomized to receive a single administration of 25 µg, 50 µg, 100 µg, or 200 µg of MM-120 or placebo. The primary objective is to determine the reduction in anxiety symptoms four weeks after the administration of MM-120, comparing the five treatment arms. Secondary objectives include assessing anxiety symptoms, safety and tolerability, as well as other measures of efficacy and quality of life up to 12 weeks after the single administration.

MindMed’s CEO and Director, Robert Barrow, expressed enthusiasm for the progress of the study’s enrollment, highlighting the efficiency and speed at which it has progressed. He credited the hard work and dedication of the study team, investigators, staff, and the patients for achieving this significant milestone.

MindMed is dedicated to the development and delivery of innovative treatments for brain health disorders. The company aims to be a global leader in the field and is developing a pipeline of novel product candidates that target neurotransmitter pathways involved in various brain health disorders. More information about the Phase 2b study and MindMed’s other initiatives can be found on the company’s website and clinical trial registry platforms.